$TPIA
Mycotopia Therapies Inc Stock $tpia

$tpia Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000109690624000907 Filed on April 23, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$498.00	$998.00	$998.00
YoY Change	0.61%	-0.3%	-0.3%
% of Gross Profit
Operating Expenses	$391.4K		$616.7K
YoY Change	233.53%		-67.12%
Operating Profit	-$391.4K		-$616.7K
YoY Change	233.53%		-67.12%
Interest Expense	$79.27K		$564.6K
YoY Change	-50.87%		-34.98%
% of Operating Profit
Other Income/Expense, Net	-$79.27K		-$564.6K
YoY Change	-50.87%		-35.51%
Pretax Income	-$470.7K		-$1.181M
YoY Change	68.89%		-57.06%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$470.7K		-$1.181M
YoY Change	68.89%		-57.06%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding	14.90M shares	14.90M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q2	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$279.9K	$279.1K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses	$500.00	$0.00
Receivables
Other Receivables
Total Short-Term Assets	$280.4K	$279.1K
YoY Change	-17.26%	-27.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$0.00	$498.00
YoY Change		-66.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.608M	$1.940M
YoY Change	160505.79%	129597.79%
TOTAL ASSETS
Total Short-Term Assets	$280.4K	$279.1K
Total Long-Term Assets	$1.608M	$1.940M
Total Assets	$1.888M	$2.219M
YoY Change	455.49%	472.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses	$374.7K	$239.7K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.813M	$4.248M
YoY Change	172.14%	455.61%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.813M	$4.248M
Total Long-Term Liabilities
Total Liabilities	$4.813M	$4.248M
YoY Change	172.14%	232.18%
SHAREHOLDERS EQUITY
Retained Earnings	-$9.858M	-$8.961M
YoY Change	17.9%	59.98%
Common Stock	$14.90K	$14.90K
YoY Change	0.01%	0.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.925M	-$2.028M
YoY Change
Total Liabilities & Shareholders Equity	$1.888M	$2.219M
YoY Change	455.49%	472.91%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$470.7K		-$1.181M
YoY Change	68.89%		-57.06%
Depreciation, Depletion And Amortization	$498.00	$998.00	$998.00
YoY Change	0.61%	-0.3%	-0.3%
Cash From Operating Activities			-$106.8K
YoY Change			-83.74%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities			$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities			$0.00
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities			-$106.8K
Cash From Investing Activities			$0.00
Cash From Financing Activities			$0.00
Net Change In Cash			-$106.8K
YoY Change			-87.89%
FREE CASH FLOW
Cash From Operating Activities			-$106.8K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-56022
CY2023	dei	Entity Registrant Name EntityRegistrantName	MYCOTOPIA THERAPIES, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-0645794
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 SE 2nd Street
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 2000
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Miami
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33131
CY2023	dei	Country Region CountryRegion	954
CY2023	dei	City Area Code CityAreaCode	233
CY2023	dei	Local Phone Number LocalPhoneNumber	3511
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	1552854	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	14896791	shares
CY2023	dei	Auditor Name AuditorName	Fruci & Associates II, PLLC
CY2023	dei	Auditor Firm AuditorFirmId	5525
CY2023	dei	Auditor Location AuditorLocation	Spokane, Washington
CY2023Q4	us-gaap	Cash Cash	279134	usd
CY2022Q4	us-gaap	Cash Cash	385899	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	279134	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	385899	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	498	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1496	usd
CY2023Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	1939781	usd
CY2022Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	0	usd
CY2023Q4	us-gaap	Assets Assets	2219413	usd
CY2022Q4	us-gaap	Assets Assets	387395	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	341358	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	225000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	239714	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	110590	usd
CY2023Q4	fil	Accrued Expenses Related Party AccruedExpensesRelatedParty	576000	usd
CY2022Q4	fil	Accrued Expenses Related Party AccruedExpensesRelatedParty	288000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1090651	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	140923	usd
CY2023Q4	fil	Shareholder Loan ShareholderLoan	2000000	usd
CY2022Q4	fil	Shareholder Loan ShareholderLoan	0	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4247723	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	764513	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	0	usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	514230	usd
CY2023Q4	us-gaap	Liabilities Liabilities	4247723	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1278743	usd
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2023Q4	fil	Liquidation Preference LiquidationPreference	0	usd
CY2022Q4	fil	Liquidation Preference LiquidationPreference	0	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14896791	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14896791	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14858357	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14858357	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	14897	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	14857	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	6917774	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	6873429	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8960981	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7779634	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2028310	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-891348	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2219413	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	387395	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	616724	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1736336	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	616724	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	1736336	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-616724	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1736336	usd
CY2023	us-gaap	Interest Expense InterestExpense	564623	usd
CY2022	us-gaap	Interest Expense InterestExpense	863330	usd
CY2023	fil	Interest Expense Related Party3 InterestExpenseRelatedParty3	0	usd
CY2022	fil	Interest Expense Related Party3 InterestExpenseRelatedParty3	7203	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-564623	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-875533	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1181347	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2611869	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1181347	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2611869	usd
CY2023	fil	Net Loss Per Share Basic And Diluted NetLossPerShareBasicAndDiluted	-0.08
CY2022	fil	Net Loss Per Share Basic And Diluted NetLossPerShareBasicAndDiluted	-0.18
CY2023	fil	Average Number Of Common Share Outstanding Basic And Diluted AverageNumberOfCommonShareOutstandingBasicAndDiluted	14884050	shares
CY2022	fil	Average Number Of Common Share Outstanding Basic And Diluted AverageNumberOfCommonShareOutstandingBasicAndDiluted	14445002	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-891348	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	635	usd
CY2023	fil	Common Stock Issued To Settle Accounts Payable And Accrued Expenses CommonStockIssuedToSettleAccountsPayableAndAccruedExpenses	43750	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1181347	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2028310	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	52021	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1022855	usd
CY2022	fil	Sale Of Preferred Shares In Private Placements SaleOfPreferredSharesInPrivatePlacements	150000	usd
CY2022	fil	Conversion Of Preferred To Common ConversionOfPreferredToCommon	0	usd
CY2022	fil	Debt Discount On Convertible Note Payable DebtDiscountOnConvertibleNotePayable	250000	usd
CY2022	fil	Conversion Of Convertible Debt In Common Stock ConversionOfConvertibleDebtInCommonStock	245645	usd
CY2022	fil	Common Stock Issued On Cashless Exercise Of Warrant CommonStockIssuedOnCashlessExerciseOfWarrant	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2611869	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-891348	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1181347	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2611869	usd
CY2023	us-gaap	Depreciation Depreciation	998	usd
CY2022	us-gaap	Depreciation Depreciation	1001	usd
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	60219	usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization	0	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	435498	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	764028	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	635	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1022855	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	160108	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	227704	usd
CY2023	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-129124	usd
CY2022	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	0	usd
CY2023	fil	Increase Decrease In Accrued Expenses Related Party IncreaseDecreaseInAccruedExpensesRelatedParty	288000	usd
CY2022	fil	Increase Decrease In Accrued Expenses Related Party IncreaseDecreaseInAccruedExpensesRelatedParty	-50000	usd
CY2023	fil	Increase Decrease In Accrued Interest Shareholder Loan IncreaseDecreaseInAccruedInterestShareholderLoan	0	usd
CY2022	fil	Increase Decrease In Accrued Interest Shareholder Loan IncreaseDecreaseInAccruedInterestShareholderLoan	10339	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-106765	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-656620	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	625000	usd
CY2023	us-gaap	Proceeds From Issuance Of Redeemable Preferred Stock ProceedsFromIssuanceOfRedeemablePreferredStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Redeemable Preferred Stock ProceedsFromIssuanceOfRedeemablePreferredStock	150000	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	250000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-225000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-106765	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-881620	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	385899	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1267519	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	279134	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	385899	usd
CY2023	us-gaap	Interest Paid InterestPaid	0	usd
CY2022	us-gaap	Interest Paid InterestPaid	17542	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2023	fil	Intangible Assets Acquired Through Promise To Issue Shares IntangibleAssetsAcquiredThroughPromiseToIssueShares	2000000	usd
CY2022	fil	Intangible Assets Acquired Through Promise To Issue Shares IntangibleAssetsAcquiredThroughPromiseToIssueShares	0	usd
CY2023	fil	Common Stock Issued To Settle Accounts Payable And Accrued Expenses CommonStockIssuedToSettleAccountsPayableAndAccruedExpenses	43750	usd
CY2022	fil	Common Stock Issued To Settle Accounts Payable And Accrued Expenses CommonStockIssuedToSettleAccountsPayableAndAccruedExpenses	0	usd
CY2023	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	150000	shares
CY2023	fil	Debt Discount On Convertible Note Payable DebtDiscountOnConvertibleNotePayable	0	usd
CY2022	fil	Debt Discount On Convertible Note Payable DebtDiscountOnConvertibleNotePayable	250000	usd
CY2023	fil	Conversion Of Convertible Debt And Interest ConversionOfConvertibleDebtAndInterest	0	usd
CY2022	fil	Conversion Of Convertible Debt And Interest ConversionOfConvertibleDebtAndInterest	245645	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-1181347	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-106765	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	279134	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4247723	usd
CY2023Q4	fil	Working Capital WorkingCapital	3968589	usd
CY2023	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="font:10pt stHtmlOvrFontNm;margin:0;color:#000000;text-align:justify"><span style="background-color:#FFFFFF"><b><i>Basis of Presentation</i></b></span></p> <p style="font:10pt stHtmlOvrFontNm;margin:0;color:#000000;text-align:justify"><span style="background-color:#FFFFFF"> </span></p> <p style="font:10pt stHtmlOvrFontNm;margin:0;color:#000000;text-align:justify"><span style="background-color:#FFFFFF">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Updates, or ASUs, of the Financial Accounting Standards Board, or FASB.</span></p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font:10pt stHtmlOvrFontNm;margin:0;color:#000000;text-align:justify"><span style="background-color:#FFFFFF"><b><i>Use of Estimates</i></b></span></p> <p style="font:10pt stHtmlOvrFontNm;margin:0;color:#000000;text-align:justify"><span style="background-color:#FFFFFF"> </span></p> <p style="font:10pt stHtmlOvrFontNm;margin:0;color:#000000;text-align:justify"><span style="background-color:#FFFFFF">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. Our financial statements include, when applicable, disclosures of estimates, assumptions, uncertainties, and markets that could affect our financial statements and future operations.</span></p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q4	us-gaap	Depreciation Depreciation	998	usd
CY2022Q4	us-gaap	Depreciation Depreciation	1001	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font:10pt stHtmlOvrFontNm;margin:0;color:#000000;text-align:justify"><span style="background-color:#FFFFFF"><b><i>Prior period reclassifications</i></b></span></p> <p style="font:13.5pt stHtmlOvrFontNm;margin:0;color:#000000"> </p> <p style="font:11pt stHtmlOvrFontNm;margin:0"><span style="font-size:10pt">We have reclassified certain amounts in prior periods to conform with current presentation. Accrued interest related to convertible notes payable in the amount of $110,590, which were reported within accounts payable and accrued expenses at December 31, 2022, have been reclassified as accrued interest on the balance sheet. </span></p>
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	110590	usd
CY2023	fil	Intangible Assets Acquired Through Promise To Issue Shares IntangibleAssetsAcquiredThroughPromiseToIssueShares	2000000	usd
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	60219	usd
CY2023Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	1939781	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	667883	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	666058	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	605839	usd
CY2023Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	1939781	usd
CY2023Q4	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.0175	pure
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	576000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	288000	usd
CY2023Q4	fil	Convertible Debt Outstanding ConvertibleDebtOutstanding	1339714	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1100000	usd
CY2023Q4	fil	Convertible Debt Interest ConvertibleDebtInterest	239714	usd
CY2022Q4	fil	Convertible Debt Outstanding ConvertibleDebtOutstanding	1210590	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1100000	usd
CY2022Q4	fil	Convertible Debt Interest ConvertibleDebtInterest	110590	usd
CY2023	fil	Aggregate Debt Discount AggregateDebtDiscount	0	usd
CY2022	fil	Aggregate Debt Discount AggregateDebtDiscount	325000	usd
CY2022	fil	Debt Discount On Convertible Note Payable Related To Financing Fees DebtDiscountOnConvertibleNotePayableRelatedToFinancingFees	75000	usd
CY2022	fil	Debt Discount On Convertible Note Payable DebtDiscountOnConvertibleNotePayable	250000	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	435498	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	764028	usd
CY2023Q4	fil	Unamortized Debt Discount UnamortizedDebtDiscount	9349	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14896791	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14896791	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14858357	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14858357	shares
CY2023	fil	Common Stock Issued To Settle Accounts Payable And Accrued Expenses CommonStockIssuedToSettleAccountsPayableAndAccruedExpenses	43750	usd
CY2022	fil	Conversion Of Convertible Debt In Common Stock ConversionOfConvertibleDebtInCommonStock	245645	usd
CY2023	fil	Initial Net Carrying Value Of Mezzanine Equity InitialNetCarryingValueOfMezzanineEquity	50000	usd
CY2023	fil	Sale Of Preferred Shares In Private Placements SaleOfPreferredSharesInPrivatePlacements	150000	usd
CY2022	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	150000	shares
CY2022	fil	Common Stock Issued On Cashless Exercise Of Warrant Shares CommonStockIssuedOnCashlessExerciseOfWarrantShares	151667	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1463784	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.67
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y9M29D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	230385	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.09
CY2022	fil	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	1.86	pure
CY2022	fil	Common Stock Issued On Cashless Exercise Of Warrant Shares CommonStockIssuedOnCashlessExerciseOfWarrantShares	151667	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1542502	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.65
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y3M14D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1922	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.01
CY2023	fil	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	0	pure
CY2023	fil	Common Stock Issued On Cashless Exercise Of Warrant Shares CommonStockIssuedOnCashlessExerciseOfWarrantShares	0	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	877758	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.01
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	666666	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.5
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y9M18D
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P2Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P1Y10M9D
CY2023	fil	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price1 ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice1	0.1
CY2022	fil	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price1 ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice1	1.09
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.57	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.70	pure
CY2023	fil	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Stock Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice	0.34
CY2022	fil	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Stock Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice	2.82
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.055	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	268214	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	207058	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	55495	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	42841	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0147	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.21	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-248083	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-548492	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-32335	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-42294	usd
CY2023	fil	Effective Income Tax Rate Reconciliation Stock Based Compensation EffectiveIncomeTaxRateReconciliationStockBasedCompensation	133	usd
CY2022	fil	Effective Income Tax Rate Reconciliation Stock Based Compensation EffectiveIncomeTaxRateReconciliationStockBasedCompensation	183632	usd
CY2023	fil	Effective Income Tax Rate Reconciliation Amortization Of Debt Discount EffectiveIncomeTaxRateReconciliationAmortizationOfDebtDiscount	91455	usd
CY2022	fil	Effective Income Tax Rate Reconciliation Amortization Of Debt Discount EffectiveIncomeTaxRateReconciliationAmortizationOfDebtDiscount	160446	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	188613	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	246709	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	217	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	12471	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	152	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	215942	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	113457	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	552122	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	363509	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	552122	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	363509	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1125576	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	464636	usd

Files In Submission

Name	View Source	Status
0001096906-24-000907-index-headers.html	Edgar Link	pending
0001096906-24-000907-index.html	Edgar Link	pending
0001096906-24-000907.txt	Edgar Link	pending
0001096906-24-000907-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tpia-20231231.htm	Edgar Link	pending
tpia-20231231.xsd	Edgar Link	pending
tpia10k_1.jpg	Edgar Link	pending
tpia10k_2.jpg	Edgar Link	pending
tpia_ex31z1.htm	Edgar Link	pending
tpia_ex32z1.htm	Edgar Link	pending
tpia-20231231_def.xml	Edgar Link	unprocessable
tpia-20231231_lab.xml	Edgar Link	unprocessable
tpia-20231231_pre.xml	Edgar Link	unprocessable
tpia-20231231_htm.xml	Edgar Link	completed
tpia-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TPIA
Mycotopia Therapies Inc Stock $tpia

2024 Q2 Form 10-K Financial Statement

#000109690624000907 Filed on April 23, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPIA Mycotopia Therapies Inc Stock $tpia

2024 Q2 Form 10-K Financial Statement

#000109690624000907 Filed on April 23, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPIA
Mycotopia Therapies Inc Stock $tpia